Ulta Beauty Q3 Earnings Beat, Company Raises Outlook

Ulta Beauty Q3 earnings topped forecasts and management raised full-year sales to $12.3 billion, sending shares higher and signaling resilience in beauty.

December 04, 2025·1 min read
View all news articles
Flat vector of a beauty counter swelling with product tiers to suggest a sales surge tied to Ulta Beauty Q3 earnings.

KEY TAKEAWAYS

  • Ulta Beauty's Q3 results beat expectations and management raised full-year sales to about $12.3 billion.
  • Margins improved year-over-year, driven by category mix, lower shrink, and operating leverage.
  • Shares surged after the beat-and-raise, reinforcing beauty demand resilience and market-share gains.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Ulta Beauty reported fiscal third-quarter revenue and profit gains that exceeded expectations, prompting a sharp stock rally. The company raised its full-year sales and profit outlook, citing broad-based strength across categories and channels.

Quarter Results and Guidance

Ulta raised its full-year sales outlook to about $12.3 billion and upgraded profit guidance, attributing the revisions to stronger-than-expected demand in the quarter. Management positioned the new targets as the baseline for the remainder of the fiscal year.

Operational Drivers and Margins

Growth was broad across makeup, skincare, haircare, and fragrance categories, with strength in both stores and e-commerce. Management cited higher traffic and a healthy average ticket as key drivers. New-product momentum, loyalty engagement, and enhanced digital experiences also contributed, especially in makeup and skincare.

Margins improved compared with the prior year, supported by a favorable category mix, lower shrinkage, and operating leverage from higher sales. This combination underpinned the decision to raise profit expectations.

Shares surged after the results as investors rewarded the beat-and-raise quarter, reversing earlier skepticism about demand in the beauty category. The performance reinforced the resilience of beauty spending amid a pressured consumer backdrop and highlighted Ulta’s continued market-share gains across key segments.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Live Nation Settlement Reached With DOJ

Live Nation Settlement Reached With DOJ

Live Nation settlement with the DOJ would force divestitures, open Ticketmaster to rivals and impose about $200 million in damages, pressuring fee income.

Hims & Hers Novo Nordisk Partnership Reported

Hims & Hers Novo Nordisk Partnership Reported

Reports say Hims & Hers Novo Nordisk partnership would let Hims sell Wegovy and Ozempic via telehealth and could alter revenue mix and positioning.

Oil Price Surge Pushes Markets Lower

Oil Price Surge Pushes Markets Lower

Oil Price Surge after strikes disrupted Strait of Hormuz flows and embedded a $14 per-barrel risk premium, pressuring stocks and lifting yields.

S&P 500 Additions: Lumentum, Coherent, Vertiv

S&P 500 Additions: Lumentum, Coherent, Vertiv

S&P 500 additions Lumentum, Coherent, Vertiv and EchoStar join effective March 13, 2026 and prompt rebalancing by funds tracking the benchmark.

Oracle OpenAI Data Center Cancellation Raises Debt Concerns

Oracle OpenAI Data Center Cancellation Raises Debt Concerns

Oracle OpenAI Data Center Cancellation heightens scrutiny of Oracle's debt and planned $50.0 billion capital raise, pressuring bond spreads, equity flows.

Servier to Buy Day One Biopharmaceuticals for $2.5B

Servier to Buy Day One Biopharmaceuticals for $2.5B

Servier to Buy Day One Biopharmaceuticals in a $2.5B cash tender offer that sets tender mechanics and regulatory timing shaping shareholder supply.